Resistant bacterial infections represent one of the biggest public health challenges today, resulting in a significant increase in morbidity and mortality linked to infectious diseases. On the other hand, Escherichia coli stands out as one of the most significant bacteria, particularly the uropathogenic (UPEC) and enteropathogenic (EPEC) variants. Infections caused by these strains have become a problem due to their ability to develop resistance to various antibiotics, thus harming therapeutic alternatives. The objective of this research was to investigate the effectiveness of phage therapy as an alternative in combating resistant bacterial infections, focusing on UPEC and enteropathogenic EPEC strains of Escherichia coli. Methodologically, it was an exploratory and comparative bibliographic review through qualitative research. As a result, it was found that future directions in phage therapy present a promising outlook, full of technological innovations, research needs and ethical considerations. The success of phage therapy as a viable alternative to treating resistant bacterial infections will depend on collaboration between different disciplines, careful consideration of ethical implications, and a commitment to ensuring that new technologies benefit society as a whole. The development of robust guidelines and regulations, along with increased public awareness, will be critical to the effective integration of phage therapy into clinical practice and public health. It was concluded that progress in this area represents a response to the bacterial resistance crisis, as it opens up new perspectives for biomedical research and clinical practice. Therefore, the continued engagement of researchers, health professionals and policy makers will be essential to ensure that phage therapy is established as an integral component in the fight against bacterial infections, benefiting public health in a broad and effective way.
Read full abstract